@article{ATM8157,
author = {Bhaskar Bhardwaj and Swaroop Revannasiddaiah and Himanshu Bhardwaj and Sree Balusu and Ali Shwaiki},
title = {Molecular targeted therapy to improve radiotherapeutic outcomes for non-small cell lung carcinoma},
journal = {Annals of Translational Medicine},
volume = {4},
number = {3},
year = {2015},
keywords = {},
abstract = {Effective treatments for non-small cell lung carcinoma (NSCLC) remain elusive. The use of concurrent chemotherapy with radiotherapy (RT) has improved outcomes, but a significant proportion of NSCLC patients are too frail to be able to tolerate an intense course of concurrent chemoradiotherapy. The development of targeted therapies ignited new hope in enhancing radiotherapeutic outcomes. The use of targeted therapies against the epidermal growth factor receptor (EGFR) has offered slight but significant benefits in concurrent use with RT for certain patients in certain situations. However, despite theoretical promise, the use of anti-angiogenics, such as bevacizumab and endostatin, has not proven clinically safe or useful in combination with RT. However, many new targeted agents against new targets are being experimented for combined use with RT. It is hoped that these agents may provide a significant breakthrough in the radiotherapeutic management of NSCLC. The current review provides a brief discussion about the targets, the targeted therapies, the rationale for the use of targeted therapies in combination with RT, and a brief review of the existing data on the subject.},
issn = {2305-5847}, url = {https://atm.amegroups.org/article/view/8157}
}